On This Page

Background of Ipamorelin

Developed in the late 1990s, ipamorelin emerged as a "third-generation" growth hormone secretagogue. Its engineering was driven by the scientific requirement for a molecule that could replicate the GH-releasing potency of compounds like GHRP-6 while eliminating the undesirable side effects of appetite stimulation and stress hormone elevation. The initial research [1] identified it as the first selective GHS, establishing a new standard for purity of hormonal response in peptide research.

While endogenous ghrelin activates receptors across various neural and endocrine tissues, ipamorelin's refined structure narrows its activation profile. This selectivity led to extensive preclinical investigation and eventual human clinical trials for postoperative ileus—a condition where gastrointestinal motility ceases after surgery. Although the trials did not meet efficacy endpoints for that specific condition, the compound remained a cornerstone of growth hormone axis research due to its safety profile and predictable GH stimulation.

Molecular Structure & Sequence

Ipamorelin is chemically defined as a synthetic pentapeptide consisting of five amino acids. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. The incorporation of non-proteinogenic residues is a critical design feature for its metabolic persistence:

  • Aib (α-aminoisobutyric acid): Enhances resistance to enzymatic degradation at the N-terminus.
  • D-2-Nal (D-2-naphthylalanine): Provides structural stability and affinity for the GHS-R1a receptor.
  • D-Phe (D-phenylalanine): Further prevents peptidase cleavage, extending the half-life compared to natural ghrelin.
  • C-terminal Amidation (NH2): Increases biological activity and protects against caboxypeptidase.

With a molecular weight of approximately 711.87 g/mol, the pentapeptide's compact size and stable bond arrangement allow it to survive in various research environments, making it suitable for multiple laboratory administration routes in animal models.

Mechanism: GHS-R1a Agonism & GH Selectivity

Ipamorelin functions as a biased agonist of the ghrelin receptor (GHS-R1a). Upon binding to these receptors in the anterior pituitary gland, it triggers the release of intracellular calcium via the phospholipase C pathway. This signaling cascade results in the secretion of growth hormone from somatotroph cells in a manner that closely mimics physiological pulsatile release [2].

The primary differentiator for ipamorelin is its lack of impact on the hypothalamic-pituitary-adrenal (HPA) axis. Unlike GHRP-2 or GHRP-6, which can bind to receptors that trigger the release of ACTH and cortisol, ipamorelin remains dormant at those specific receptor sites. Research has consistently observed that even at supratherapeutic doses (up to 100 times the dose required for maximum GH release), ipamorelin does not induce significant elevations in cortisol or prolactin [1, 3].

Preclinical Evidence Table

Research Domain Observed Parameters Research Maturity Key Findings
GH Secretion Pulsatile GH peaks, IGF-1 levels High (Multiple Models) Dose-dependent GH release; peak reach within 30-40 min [3].
Bone Health Mineral density, longitudinal growth Intermediate Significant increase in bone mineral content and longitudinal growth [2, 4].
Gastrointestinal Gastric emptying, ileus recovery High (Clinical) Improves gastric motility; failed Phase II for post-op ileus efficacy.
Body Composition Nitrogen retention, lean mass Intermediate Inhibits corticosteroid-induced catabolism and muscle wasting [4].

Impact on Bone Growth & Mineralization

In skeletal research, ipamorelin has been investigated for its ability to promote longitudinal bone growth in rodent models. Studies involving hypophysectomized rats (animals with the pituitary gland removed) demonstrated that ipamorelin administration significantly increased tibial growth plate width [2]. This suggests that the peptide acts directly or through IGF-1 mediation to stimulate chondrocyte proliferation.

Furthermore, and perhaps more importantly for metabolic research, ipamorelin was observed to counteract the catabolic effects of corticosteroids. Dexamethasone-induced bone loss and muscle wasting were significantly mitigated when co-administered with ipamorelin, suggesting a protective role for the GH axis in "wasting" disease models [4].

Research Limitations & Safety Data

Despite its high selectivity, ipamorelin research is confined strictly to the laboratory. The failure of clinical trials for postoperative ileus illustrates a common gap between animal model success and human clinical application. In those trials, while gastric emptying was slightly accelerated, the clinical endpoint of significantly reducing the time to first bowel movement or solid food tolerance was not met with statistical significance [5].

As a research compound, ipamorelin is generally regarded as having a high safety margin in animal models due to its lack of HPA axis activation. However, because it is not approved for any human use, long-term safety data in humans is non-existent. Research protocols often note its quick elimination half-life (approx. 2 hours), which necessitates frequent administration windows in certain longitudinal studies.

Researchers investigating growth hormone secretagogues often compare ipamorelin to other analogs in the short chain aminos category:

  • GHRP-6: A non-selective GHS that stimulates intense appetite and cortisol release; often used as a baseline for GHS-R1a potency.
  • BPC-157: Frequently researched alongside Ipamorelin for synergistic effects in tissue repair and gastrointestinal stability. See our BPC-157 Research Review for more.
  • CJC-1295: A GHRH analog often used in combination studies to observe synergistic GH release, as it targets the GHRH receptor rather than the ghrelin receptor.
  • TB-500: Often paired with GHS research in wound healing models. Read the TB-500 Review here.

Where to Source for Research

For scientific investigations, it is imperative to source ipamorelin from suppliers that provide high-purity, verified compounds. The following laboratories are recognized for providing research-grade materials for in vitro and animal studies:

Frequently Asked Questions

What is the primary mechanism of Ipamorelin?

Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a). It mimics the action of ghrelin by binding to receptors in the anterior pituitary gland, which stimulates the pulsatile release of growth hormone (GH) without significantly affecting other pituitary hormones like cortisol or prolactin.

How does Ipamorelin differ from GHRP-6 in research settings?

The defining difference is selectivity. While both stimulate GH release, GHRP-6 often causes dose-dependent elevations in cortisol, ACTH, and prolactin, and is a potent appetite stimulant. Ipamorelin is highly selective for GH release and shows negligible impact on stress hormones or appetite in most experimental models.

What is the chemical structure of Ipamorelin?

Ipamorelin is a pentapeptide with the specific amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It replaces the natural amino acids with D-isomers and non-natural residues like alpha-aminoisobutyric acid (Aib) to increase metabolic stability and resistance to enzyme degradation during research studies.

Has Ipamorelin been approved for human use?

No, Ipamorelin is not approved by the FDA or any other regulatory body for human or veterinary medical use. Although it reached Phase II clinical trials for postoperative ileus, the trials were discontinued. It remains strictly a research chemical for laboratory and animal study purposes only.

What are the common research applications for Ipamorelin?

Ipamorelin is primarily used to study growth hormone axes, longitudinal bone growth, and lean mass preservation. Due to its selectivity, it is also researched for its potential to improve gastric emptying and counteract catabolic states without the confounding variables of elevated cortisol or prolactin levels.

Works Cited

  1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-61. PMID: 9781084. DOI: 10.1530/eje.0.1390552.
  2. Johansen PB, et al. The growth hormone-releasing action of ipamorelin, a new growth hormone secretagogue, in the rat. Endocrinology. 1999;140(8):3528-35. PMID: 10419266. DOI: 10.1210/endo.140.8.6912.
  3. Gobburu JY, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-16. PMID: 10499645. DOI: 10.1023/a:1011986422709.
  4. Hansen BS, et al. Ipamorelin, a ghrelin receptor agonist, inhibits dexamethasone-induced catabolism in rats. Journal of Endocrinology. 1999;160(3):497-502. PMID: 10080757. DOI: 10.1677/joe.0.1600497.
  5. Greenwood-Van Meerveld, B., et al. The selective growth hormone secretagogue ipamorelin, but not ghrelin, improves postoperative ileus in a rodent model. Neurogastroenterology & Motility. 2011;23(11):1024-e419. PMID: 21914041. DOI: 10.1111/j.1365-2982.2011.01794.x.